MA39187A1 - Dérivés d'acide hétéroaryl butanoïque en tant qu'inhibiteurs de la lta4h - Google Patents

Dérivés d'acide hétéroaryl butanoïque en tant qu'inhibiteurs de la lta4h

Info

Publication number
MA39187A1
MA39187A1 MA39187A MA39187A MA39187A1 MA 39187 A1 MA39187 A1 MA 39187A1 MA 39187 A MA39187 A MA 39187A MA 39187 A MA39187 A MA 39187A MA 39187 A1 MA39187 A1 MA 39187A1
Authority
MA
Morocco
Prior art keywords
butanoic acid
lta4h
derivatives
inhibitors
heteroaryl butanoic
Prior art date
Application number
MA39187A
Other languages
English (en)
Inventor
Birgit Bollbuck
Christian Markert
Wofgang Miltz
Till Roehn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2014/067086 external-priority patent/WO2015092740A1/fr
Publication of MA39187A1 publication Critical patent/MA39187A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention décrit de nouveaux dérivés d'acide hétéroaryl butanoïque qui s'avèrent être de bons candidats médicaments, surtout en ce qui concerne la leucotriène a4 hydrolase (lta4h). La présente invention concerne également des compositions pharmaceutiques comprenant ces nouveaux dérivés d'acide hétéroaryl butanoïque, des procédés d'utilisation de ces composés dans le traitement de diverses maladies et de divers troubles, et des procédés de préparation de ces nouveaux composés.
MA39187A 2013-12-20 2014-12-18 Dérivés d'acide hétéroaryl butanoïque en tant qu'inhibiteurs de la lta4h MA39187A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199138 2013-12-20
PCT/IB2014/067086 WO2015092740A1 (fr) 2013-12-20 2014-12-18 Dérivés d'acide hétéroaryl butanoïque en tant qu'inhibiteurs de la lta4h

Publications (1)

Publication Number Publication Date
MA39187A1 true MA39187A1 (fr) 2017-09-29

Family

ID=49876468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39187A MA39187A1 (fr) 2013-12-20 2014-12-18 Dérivés d'acide hétéroaryl butanoïque en tant qu'inhibiteurs de la lta4h

Country Status (1)

Country Link
MA (1) MA39187A1 (fr)

Similar Documents

Publication Publication Date Title
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA44474B1 (fr) Inhibiteurs de la ferroportine
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
BR112014026703A2 (pt) inibidores de dna-pk
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA38276A1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
WO2014028589A3 (fr) Composés d'acide benzoïque substitués par un 4-hétéroaryle à titre d'inhibiteurs de rorgammat et leurs utilisations
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MX391620B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
MA38679B1 (fr) Modulateurs du récepteur de cxcr7